UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487

Noda K, Nishiwaki Y, Kawahara M, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91

Hahn KK, Wolff JJ, Kolesar JM (2006) Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 63:2211–2217

Innocenti F, Undevia SD, Iyer L, et al. (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388

Ando Y, Saka H, Ando M, et al. (2000) Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926

Ramchandani RP, Wang Y, Booth BP, et al. (2007) The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78–86

Monaghan G, Ryan M, Seddon R, et al. (1996) Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet 347:578–581

Ando Y, Chida M, Nakayama K, et al. (1998) The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8:357–360

Kaniwa N, Kurose K, Jinno H, et al. (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos 33:458–465

Sai K, Saeki M, Saito Y, et al. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501–515

Minami H, Sai K, Saeki M, et al. (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497–504

Araki K, Fujita K, Ando Y, et al. (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255–1259

Han JY, Lim HS, Shin ES, et al. (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244

Charasson V, Bellott R, Meynard D, et al. (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528–535

de Jong FA, Scott-Horton TJ, Kroetz DL, et al. (2007) Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42–49

Nozawa T, Minami H, Sugiura S, et al. (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434–439

Xiang X, Jada SR, Li HH, et al. (2006) Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 16:683–691

Akaba K, Kimura T, Sasaki A, et al. (1999) Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet 44:22–25

Maruo Y, Nishizawa K, Sato H, et al. (1999) Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 103:1224–1227

Bancroft JD, Kreamer B, Gourley GR (1998) Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr 132:656–660

Ciotti M, Basu N, Brangi M, et al. (1999) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDPglucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199–202

Gagne JF, Montminy V, Belanger P, et al. (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608–617

Fujita K, Ando Y, Nagashima F, et al. (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60:515–522

Hoskins, JM, Godberg, RM, Qu, P, et al. (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia. J Natl Cancer Inst 99:1290–1295

Nishizato Y, Ieiri I, Suzuki H, et al. (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565

Tokui T, Nakai D, Nakagomi R, et al. (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16:904–908